Nasus Pharma

Nasus Pharma EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Nasus Pharma (NSRX) as of Oct 26, 2026 is -9.46. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -76.42 — a change of -87.62% (higher).

EV/FCF

-9.46

YoY

-87.62%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Nasus Pharma is 2025 -9.46 . EV/FCF (Enterprise Value to Free Cash Flow) of Nasus Pharma was 2024 -76.42 . It decreases by -87.62% higher compared to the previous year.

The Nasus Pharma EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2022
-41.96 USD
Jan 1, 2023
-49.38 USD
Jan 1, 2024
-76.42 USD
Jan 1, 2025
-9.46 USD
The Nasus Pharma EV/FCF history
YEAREV/FCFYoY
-9.46-87.62%
-76.42+54.74%
-49.38+17.69%
-41.96—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nasus Pharma Stock analysis

What does Nasus Pharma do? Nasus Pharma Ltd is an Israel-based pharmaceutical company specializing in microsphere technology for intranasal powder-based drug delivery systems. The firm manufactures pharmaceutical preparations designed for rapid, non-invasive administration of medications targeting conditions like anaphylaxis and opioid overdose. Their products focus on fast absorption, ease of use, and effectiveness in emergency scenarios, enabling caregivers, non-professionals, and medical professionals to administer life-saving treatments without specialized training. Nasus Pharma Ltd's formulations aim to improve access to critical medications by simplifying administration in urgent situations. The company's primary products are intranasal powder-based drug delivery systems utilizing microsphere technology. These systems are tailored for conditions requiring immediate intervention, such as anaphylaxis and opioid overdose. The firm targets medical doctors, emergency nurses, and caregivers as key buyers, emphasizing the products' role in critical care settings where speed and simplicity are essential. Nasus Pharma Ltd positions itself as a provider of accessible emergency treatments that bridge gaps in traditional medical administration. Nasus Pharma Ltd's business model centers on developing and commercializing pharmaceutical preparations that leverage microsphere technology for intranasal delivery. The company focuses on creating solutions for life-saving treatments that can be administered by non-specialists, thereby expanding the reach of critical medications. By addressing the need for rapid, non-invasive drug delivery in emergencies, Nasus Pharma Ltd caters to healthcare providers and emergency responders who require reliable, easy-to-use products during critical incidents. Nasus Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nasus Pharma stock

EV/FCF (Enterprise Value to Free Cash Flow) of Nasus Pharma is -9.46 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Nasus Pharma changed from -76.42 to -9.46, representing a -87.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Nasus Pharma since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Nasus Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Nasus Pharma

All Key Metrics — Nasus Pharma